Michael G Benatar


  • 6999 Citations
1994 …2023
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 3 Similar Profiles
Amyotrophic Lateral Sclerosis Medicine & Life Sciences
Myasthenia Gravis Medicine & Life Sciences
Mutation Medicine & Life Sciences
Polyneuropathies Medicine & Life Sciences
Biomarkers Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences
Prednisone Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2008 2023

Asymptomatic Diseases
Organized Financing
Antisense Oligonucleotides

University of Miami NeuroNEXT Trial Site

Benatar, M. G.

National Institutes of Health


Project: Research projectResource-Related Research Projects--Cooperative Agreements

National Institute of Neurological Disorders and Stroke
Clinical Trials
Hispanic Americans
Research Personnel

Multi-Center ALS Biomarker Validation Study (CReATe Biomarkers)

Benatar, M. G.

National Institutes of Health


Project: Research projectResearch Project--Cooperative Agreements

Validation Studies
Cerebrospinal Fluid
Intermediate Filaments
Therapeutic Uses

Clinical Research in ALS & related disorders for Therapeutic Development (CREATE)

Benatar, M. G.

National Institutes of Health


Project: Research projectSpecialized Center--Cooperative Agreements

Patient Advocacy
Rare Diseases
Gene-Environment Interaction
Amyotrophic Lateral Sclerosis
Environmental Exposure
Mendelian Randomization Analysis

Research Output 1994 2019

Editorial: We may need large trials to find treatments for neurodegenerative diseases

Schoenfeld, D. A. & Benatar, M. G., Jan 1 2019, (Accepted/In press) In : Clinical Trials.

Research output: Contribution to journalArticle

Neurodegenerative Diseases
Sample Size
Parkinson Disease
Alzheimer Disease
Clinical Trials

Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis

Clifford, K. M., Hobson-Webb, L. D., Benatar, M. G., Burns, T. M., Barnett, C., Silvestri, N. J., Howard, J. F., Visser, A., Crum, B. A., Nowak, R., Beekman, R., Kumar, A., Ruzhansky, K., Chen, I. H. A., Pulley, M. T., Laboy, S. M., Fellman, M. A., Howard, D. B., Kolb, N. A., Greene, S. M. & 4 othersPasnoor, M., Dimachkie, M. M., Barohn, R. J. & Hehir, M. K., Jan 1 2019, (Accepted/In press) In : Muscle and Nerve.

Research output: Contribution to journalArticle

Myasthenia Gravis
Plasma Exchange

ALSUntangled 41: “Eric Is Winning”

The ALSUntangled Group, Jan 2 2018, In : Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 19, 1-2, p. 157-160 4 p.

Research output: Contribution to journalArticle

3 Citations

Developing treatment guidelines for myasthenia gravis

The MGFA Task Force On Mg Treatment Guidance, Jan 1 2018, In : Annals of the New York Academy of Sciences. 1412, 1, p. 95-101 7 p.

Research output: Contribution to journalReview article

Intravenous Immunoglobulins
Myasthenia Gravis
Immunosuppressive Agents
Protein-Tyrosine Kinases
17 Citations

Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

Answer ALS Foundation, Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) Consortium, SLAGEN Consortium, French ALS Consortium, Project MinE ALS Sequencing Consortium, ITALSGEN Consortium, Genomic Translation for ALS Care (GTAC) Consortium, ALS Sequencing Consortium & NYGC ALS Consortium, Mar 21 2018, In : Neuron. 97, 6, p. 1268-1283.e6

Research output: Contribution to journalArticle

Genome-Wide Association Study